Inspire hope today for
a better world tomorrow
Tikva Allocell is focused on creating therapy using our proprietary IP protected platform to drive the next breakthrough in cancer and autoimmune therapies.
At Tikva Allocell we inspire hope today, for a better tomorrow.
Cell therapy company focused on a Second Generation Allogeneic EBV-Specific T cell (ALLO EBVST) platform to target difficult-to-treat cancers.
We develop safe, effective, affordable T cell therapies.
At Tikva Allocell, our mission is to develop safe, effective, readily available and affordable “off-the-shelf” T cell therapies by leveraging excellent safety profile of ALLO EBVST and proprietary technologies that enhance the T cell's performance to treat cancer and autoimmune diseases.
Diverse Strategies
One Goal
01
Allogeneic EBVST
Well tolerated and able to be enhanced with novel strategies to improve efficacy, persistence and safety.
02
Solid Tumor Target
Focused on unmet medical need which has the greatest potential to benefit from novel CAR-T technology.
03
Oncolytic Virus
Enhanced tumor killing through modification of tumor microenvironment to further improve T cell efficacy.